The case-control study of the association between pre-alcoholic cirrhosis and new-onset non-alcoholic fatty liver disease after liver transplantation

Abstract

Abstract: Objective To explore whether alcoholic cirrhosis before liver transplantation is a risk factor for non-alcoholic fatty liver disease (NAFLD) after liver transplantation.Methods Continuously collected the clinical data of patients with liver transplantation from May 2015 to May 2019 in the Fifth Medical Center of PLA General Hospital. New-onset NAFLD patients were screened, those who met the criteria for new-onset NAFLD were enrolled into the case group, and patients without NAFLD after liver transplantation were grouped into the control group. Analyzed the differences between the two groups of new-onset NAFLD patients and non-NAFLD patients. Logistic regression was used to analyze whether pre-transplant alcoholic cirrhosis was a risk factor for new-onset NAFLD.Results Finally, 136 patients were eligible, 15 of them who diagnosed with NAFLD were grouped into case group, and 121 of them who without NAFLD were into control group. The incidence of new-onset NAFLD at 1 year after liver transplantation was 11.03%. Compared with patients without NAFLD, preoperative median BMI (27.85 vs 23.17, P=0.003), indication for alcoholic cirrhosis (66.7% vs 23.1%, P=0.001), preoperative history of hypertension (33.3% vs 5.4%, P=0.016), and currently ALT level at 1 year after liver transplantation (24.0 U/L vs 21.5 U/L, P=0.012) were statistically significant between the two groups. Logistic regression showed that liver transplantation indications for alcoholic cirrhosis (OR=4.79, 95%CI: 1.35-16.98) and pre-liver transplantation high BMI (OR=1.23, 95%CI: 1.05-1.46) were risk factors for new-onset NAFLD.Conclusion Alcoholic cirrhosis before liver transplantation is a risk factor for new onset NAFLD.

Key words: New-onset non-alcoholic fatty liver disease, Alcoholic cirrhosis, liver transplantation

FENG Dan-ni, ZHANG Da-li, HE Xi, ZHANG Xiao-feng, NIU Xiao-feng, LI Zhi-jie, LI Li-xin, LIU Jia, ZHUANG Yun-long, LIU Zhen-wen, WANG Hong-bo. The case-control study of the association between pre-alcoholic cirrhosis and new-onset non-alcoholic fatty liver disease after liver transplantation[J]. Chinese Hepatolgy, 2022, 27(1): 95-97.

References

[1] Losurdo G, Castellaneta A, Rendina M, et al. Systematic review with meta-analysis: de novo non-alcoholic fatty liver disease in liver-transplanted patients. Aliment Pharmacol Ther,2018,47:704-14.
[2] Pais R, Barritt ASt, Calmus Y, et al. NAFLD and liver transplantation: current burden and expected challenges. J Hepatol,2016,65:1245-57.
[3] Narayanan P, Mara K, Izzy M, et al. Recurrent or De Novo Allograft Steatosis and Long-term Outcomes After Liver Transplantation. Transplantation,2019,103:e14-e21.
[4] Eslam M, Newsome PN, Sarin SK, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol,2020,73:202-209.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪性肝病专家委员会.酒精性肝病防治指南(2018年更新版).临床肝胆病杂志,2018,34(05):939-946.
[6] Germani G, Laryea M, Rubbia-Brandt L, et al. Management of Recurrent and De Novo NAFLD/NASH After Liver Transplantation. Transplantation,2019,103:57-67.
[7] Salameh H, Raff E, Erwin A, et al. PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease. Am J Gastroenterol,2015,110(6):846-856.
[8] Buch S, Stickel F, Trépo E, et al. A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis. Nat Genet,2015,47(12):1443-1448.
[9] Romano A, Friuli M, Del Coco L, et al. Chronic oleoylethanolamide treatment decreases hepatic triacylglycerol level in rat liver by a PPARγ/SREBP-mediated suppression of fatty acid and triacylglycerol synthesis. Nutrients,2021,13.
[10] Seitz HK, Bataller R, Cortez-Pinto H, et al. Alcoholic liver disease. Nat Rev Dis Primers,2018,4:16.
[11] Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. J Hepatol,2020,73(4):757-770.
[12] Stattermayer AF, Halilbasic E, Wrba F, et al. Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. J Hepatol,2020,73:651-663.
[13] Gitto S, Villa E. Non-alcoholic fatty liver disease and metabolic syndrome after liver transplant. Int J Mol Sci,2016,17:490.
[14] Fan JG, Kim SU, Wong VW. New trends on obesity and NAFLD in Asia. J Hepatol,2017,67:862-873.
[15] Eslam M, Sanyal AJ, et al. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology,2020,158(7):1999-2014.
[16] Dasarathy S, Dasarathy J, Khiyami A, et al. Validity of real time ultrasound in the diagnosis of hepatic steatosis: a prospective study. J Hepatol,2009,51(6):1061-1067.